Chemotherapy drug paclitaxel tested for Hard-to-Treat GIST
NCT ID NCT03944304
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested the chemotherapy drug paclitaxel in 40 patients with advanced or metastatic gastrointestinal stromal tumor (GIST) whose cancer had stopped responding to three standard treatments: imatinib, sunitinib, and regorafenib. The study focused on patients with low levels of a protein called P-glycoprotein, as earlier research suggested paclitaxel might work better in this group. The goal was to see if the drug could control tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel (a chemotherapy drug)
What this could lead to
If it works, this could provide a new treatment option for patients with advanced GIST who have run out of standard therapies.
What could go wrong
This is a small, early-phase study (40 participants) with no control group. Previous trials showed limited benefit, and the drug may only help a subset of patients with low P-glycoprotein expression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea